Cellectis (CLLS) Stock Price
Cellectis Price
Revenue has compounded at 17.3% per year over the past 18 years to 72.95 M USD. Cellectis's net margin stands at -92.7%, up from -116.7% several years earlier.
Cellectis stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cellectis business model & stock analysis
Frequently asked questions about Cellectis
13 analysts currently rate the Cellectis stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Cellectis to generate revenue of 53.56 M USD and earnings per share of -0.58 USD.
Converted at the current exchange rate, the Cellectis share trades at 0.93 EUR (1.04 USD).
The expected revenue of Cellectis is 53.56 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Cellectis is -58.33 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cellectis is currently -1.79. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cellectis stock.
The price-to-sales ratio (P/S) of Cellectis is currently 1.95. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cellectis stock.
The Eulerpool Quality Score for Cellectis is 3/10.
The ISIN of Cellectis is US15117K1034. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Cellectis is A14QZE. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Cellectis is CLLS. The ticker symbol is used to trade Cellectis shares on the stock exchange.
Cellectis stock
Cellectis Peer Group
All fundamentals and in-depth analysis of Cellectis
Our stock analysis for Cellectis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cellectis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.